Paramyotonia Congenita (PMC) Cell Models for Research

Paramyotonia Congenita (PMC) is a rare hereditary neuromuscular disorder with an estimated prevalence of 1 in 100,000 to 1 in 200,000 worldwide (WHO, 2023). It is characterized by myotonia (muscle stiffness) and episodic weakness, often triggered by cold or exercise. The disease is not typically life-threatening, but it significantly impacts quality of life. There is no cure; treatment focuses on symptom management. The rarity and well-defined genetic basis make PMC an excellent model for studying ion channel function and muscle physiology.

PMC is caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4. This monogenic disorder provides a clear genotype-phenotype correlation, making it ideal for functional studies. Research on PMC contributes to understanding channelopathies, muscle excitability, and potential therapeutic targets. Public datasets, such as ClinVar and UniProt, provide mutation information, while DepMap offers cell line dependency data. Open questions include the precise molecular mechanisms of cold-induced myotonia and the development of targeted therapies.

PMC arises from mutations in SCN4A that alter the function of the Nav1.4 sodium channel. The primary pathogenic mechanism involves:

• • Impaired Inactivation: Many PMC mutations, such as p.Val1293Ile, disrupt fast inactivation of the channel, leading to persistent sodium current.
• • Enhanced Activation: Some mutations shift the voltage dependence of activation to more negative potentials, increasing channel opening.
• • Cold Sensitivity: Cold temperatures exacerbate these defects, likely due to altered membrane fluidity or direct effects on channel gating.

These changes result in prolonged muscle fiber depolarization, causing myotonia and weakness.

Data from ClinVar and COSMIC indicate that missense mutations are the most common, with specific hotspots such as p.Val1293Ile and p.Thr1313Met.

PMC primarily affects the sodium channel, but downstream signaling pathways are also impacted:

• • Muscle Excitability: Altered sodium currents affect action potential propagation and muscle contraction.
• • Calcium Homeostasis: Prolonged depolarization may affect calcium handling, contributing to weakness.
• • Energy Metabolism: Chronic myotonia may increase energy demand, affecting metabolic pathways.

Key nodes include the sodium channel itself, voltage-gated potassium channels, and calcium release channels (ryanodine receptor).

Organoids derived from patient iPSCs are also emerging as more physiologically relevant models, allowing study of muscle development and function in a 3D context.

• • Genetically Engineered Mouse Models (GEMMs): Knock-in mice carrying PMC mutations (e.g., p.Val1293Ile) recapitulate myotonia and cold sensitivity.
• • Induced Models: Pharmacological agents like veratridine can induce myotonia in wild-type mice.
• • Patient-Derived Xenografts (PDX): Not applicable for PMC as it is not a cancer, but muscle cell xenografts are possible.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific SCN4A mutations. For example:

• • SCN4A Knockout Cell Lines: Complete loss of Nav1.4 to study channel function.
• • Knock-in Cell Lines: Introduction of specific point mutations (e.g., p.Val1293Ile) to model disease.

These models are commercially available and sequence-verified, ensuring reproducibility. They are essential for functional studies, drug screening, and understanding mutation-specific effects.

Knockout and knock-in lines allow validation of SCN4A mutations' pathogenicity. For example, introducing a variant into a wild-type background and measuring sodium currents can confirm its effect. This is crucial for classifying variants of unknown significance.

Isogenic pairs (wild-type vs. mutant) are used to screen drugs that modulate sodium channel activity. For instance, mexiletine, a sodium channel blocker, is commonly used; gene-edited cells can test its efficacy on specific mutations. Resistance mechanisms can also be studied by exposing cells to drugs and selecting for resistant clones.

CRISPR screens can identify genes that modify the phenotype of mutant SCN4A cells. Synthetic lethality screens may reveal targets that, when inhibited, selectively kill mutant cells, providing potential therapeutic avenues.